Intellia Therapeutics (NTLA) Competitors $12.27 +0.70 (+6.05%) Closing price 04:00 PM EasternExtended Trading$12.36 +0.09 (+0.73%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NTLA vs. BEAM, CRSP, EDIT, TWST, MRUS, PTCT, ACAD, MENS, PCVX, and KRYSShould you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Twist Bioscience (TWST), Merus (MRUS), PTC Therapeutics (PTCT), ACADIA Pharmaceuticals (ACAD), Jyong Biotech (MENS), Vaxcyte (PCVX), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Intellia Therapeutics vs. Its Competitors Beam Therapeutics CRISPR Therapeutics Editas Medicine Twist Bioscience Merus PTC Therapeutics ACADIA Pharmaceuticals Jyong Biotech Vaxcyte Krystal Biotech Intellia Therapeutics (NASDAQ:NTLA) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends. Which has preferable valuation and earnings, NTLA or BEAM? Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntellia Therapeutics$57.88M22.76-$519.02M-$4.69-2.62Beam Therapeutics$63.52M36.49-$376.74M-$4.50-5.09 Is NTLA or BEAM more profitable? Beam Therapeutics has a net margin of -661.31% compared to Intellia Therapeutics' net margin of -908.48%. Beam Therapeutics' return on equity of -43.15% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intellia Therapeutics-908.48% -57.48% -45.04% Beam Therapeutics -661.31%-43.15%-31.06% Which has more risk and volatility, NTLA or BEAM? Intellia Therapeutics has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500. Do insiders and institutionals hold more shares of NTLA or BEAM? 88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 3.1% of Intellia Therapeutics shares are held by insiders. Comparatively, 3.5% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend NTLA or BEAM? Intellia Therapeutics currently has a consensus price target of $27.11, suggesting a potential upside of 120.95%. Beam Therapeutics has a consensus price target of $46.40, suggesting a potential upside of 102.53%. Given Intellia Therapeutics' higher possible upside, analysts clearly believe Intellia Therapeutics is more favorable than Beam Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intellia Therapeutics 1 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.56Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 3 Strong Buy rating(s) 3.08 Does the media prefer NTLA or BEAM? In the previous week, Intellia Therapeutics had 11 more articles in the media than Beam Therapeutics. MarketBeat recorded 18 mentions for Intellia Therapeutics and 7 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.84 beat Intellia Therapeutics' score of 0.71 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBeam Therapeutics beats Intellia Therapeutics on 12 of the 17 factors compared between the two stocks. Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NTLA vs. The Competition Export to ExcelMetricIntellia TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.24B$3.12B$5.73B$10.31BDividend YieldN/A2.36%5.90%4.63%P/E Ratio-2.6221.1675.8626.51Price / Sales22.76446.35528.74123.58Price / CashN/A45.4037.1760.46Price / Book1.439.6212.796.29Net Income-$519.02M-$53.28M$3.28B$270.51M7 Day Performance3.28%0.31%0.22%2.15%1 Month Performance11.65%4.58%4.61%6.35%1 Year Performance-42.96%9.24%68.33%25.48% Intellia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NTLAIntellia Therapeutics4.4501 of 5 stars$12.27+6.1%$27.11+121.0%-47.6%$1.24B$57.88M-2.62600BEAMBeam Therapeutics3.026 of 5 stars$19.95-4.5%$48.45+142.9%-19.1%$2.02B$63.52M-4.43510Analyst DowngradeHigh Trading VolumeCRSPCRISPR Therapeutics2.7816 of 5 stars$54.10-1.4%$71.60+32.3%+18.2%$4.92B$37.31M-9.96460EDITEditas Medicine4.1928 of 5 stars$2.79+1.1%$5.10+82.8%-32.4%$250.88M$32.31M-0.98230TWSTTwist Bioscience3.9473 of 5 stars$26.25+1.9%$49.40+88.2%-45.2%$1.58B$312.97M-18.10990Positive NewsMRUSMerus2.7728 of 5 stars$67.19-0.4%$88.75+32.1%+35.8%$5.08B$36.13M-12.2237Positive NewsPTCTPTC Therapeutics3.7221 of 5 stars$56.95-0.5%$69.00+21.2%+73.5%$4.52B$806.78M8.171,410Insider TradeACADACADIA Pharmaceuticals4.3265 of 5 stars$25.39+0.5%$28.88+13.7%+51.2%$4.28B$957.80M19.09510MENSJyong BiotechN/A$55.68+6.4%N/AN/A$4.23BN/A0.0031News CoverageGap UpPCVXVaxcyte2.1736 of 5 stars$32.41-1.8%$130.00+301.1%-73.3%$4.21BN/A-7.89160Positive NewsKRYSKrystal Biotech4.9516 of 5 stars$145.20-3.4%$210.38+44.9%-22.8%$4.20B$290.52M29.51210News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies Beam Therapeutics Alternatives CRISPR Therapeutics Alternatives Editas Medicine Alternatives Twist Bioscience Alternatives Merus Alternatives PTC Therapeutics Alternatives ACADIA Pharmaceuticals Alternatives Jyong Biotech Alternatives Vaxcyte Alternatives Krystal Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NTLA) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
